These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17767974)

  • 1. Prevention of HIV/AIDS among injecting drug users in Russia: opportunities and barriers to scaling-up of harm reduction programmes.
    Tkatchenko-Schmidt E; Renton A; Gevorgyan R; Davydenko L; Atun R
    Health Policy; 2008 Feb; 85(2):162-71. PubMed ID: 17767974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qualitative evaluation of a peer-based needle syringe programme in Vietnam.
    Ngo AD; Schmich L; Higgs P; Fischer A
    Int J Drug Policy; 2009 Mar; 20(2):179-82. PubMed ID: 18242971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Social evils' and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam.
    Hammett TM; Wu Z; Duc TT; Stephens D; Sullivan S; Liu W; Chen Y; Ngu D; Des Jarlais DC
    Addiction; 2008 Jan; 103(1):137-45. PubMed ID: 18028519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advocacy for harm reduction in China: a new era dawns.
    Reid G; Aitken C
    Int J Drug Policy; 2009 Jul; 20(4):365-70. PubMed ID: 19097773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV prevention for injection drug users in China and Vietnam: policy and research considerations.
    Hammett TM; Des Jarlais D; Johnston P; Kling R; Ngu D; Liu W; Chen Y; Van LK; Donghua M
    Glob Public Health; 2007; 2(2):125-39. PubMed ID: 19280395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of barriers and facilitators of HIV treatment among injection drug users.
    Wood E; Kerr T; Tyndall MW; Montaner JS
    AIDS; 2008 Jul; 22(11):1247-56. PubMed ID: 18580603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Global Fund's leadership on harm reduction: 2002-2009.
    Atun R; Kazatchkine M
    Int J Drug Policy; 2010 Mar; 21(2):103-6. PubMed ID: 20171865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why do health systems matter? Exploring links between health systems and HIV response: a case study from Russia.
    Tkatchenko-Schmidt E; Atun R; Wall M; Tobi P; Schmidt J; Renton A
    Health Policy Plan; 2010 Jul; 25(4):283-91. PubMed ID: 20144936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary syringe exchange as a model for HIV prevention programs in the Russian Federation.
    Irwin K; Karchevsky E; Heimer R; Badrieva L
    Subst Use Misuse; 2006; 41(6-7):979-99. PubMed ID: 16809182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid scale up of harm reduction in China.
    Sullivan SG; Wu Z
    Int J Drug Policy; 2007 Mar; 18(2):118-28. PubMed ID: 17689354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for dealing with HIV / AIDS in the former Soviet Union.
    Burrows D
    Dev Bull; 2000 Jun; (52):49-51. PubMed ID: 12179451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obstacles in provision of anti-retroviral treatment to drug users in Central and Eastern Europe and Central Asia: a regional overview.
    Bobrova N; Sarang A; Stuikyte R; Lezhentsev K
    Int J Drug Policy; 2007 Aug; 18(4):313-8. PubMed ID: 17689380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The transition to harm reduction: understanding the role of non-governmental organisations in Malaysia.
    Narayanan S; Vicknasingam B; Robson NM
    Int J Drug Policy; 2011 Jul; 22(4):311-7. PubMed ID: 21300533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coverage to curb the emerging HIV epidemic among injecting drug users in Pakistan: delivering prevention services where most needed.
    Emmanuel F; Fatima M
    Int J Drug Policy; 2008 Apr; 19 Suppl 1():S59-64. PubMed ID: 18281206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malaysia and harm reduction: the challenges and responses.
    Reid G; Kamarulzaman A; Sran SK
    Int J Drug Policy; 2007 Mar; 18(2):136-40. PubMed ID: 17689356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of harm reduction in Central and Eastern Europe and Central Asia.
    Sarang A; Stuikyte R; Bykov R
    Int J Drug Policy; 2007 Mar; 18(2):129-35. PubMed ID: 17689355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining the policy climate for HIV prevention in the Caribbean tourism sector: a qualitative study of policy makers in the Dominican Republic.
    Padilla MB; Reyes AM; Connolly M; Natsui S; Puello A; Chapman H
    Health Policy Plan; 2012 May; 27(3):245-55. PubMed ID: 21422044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving from a project to programmatic response: scaling up harm reduction in Asia.
    Chatterjee A; Sharma M
    Int J Drug Policy; 2010 Mar; 21(2):134-6. PubMed ID: 20079618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development of peer educator-based harm reduction programmes in Northern Vietnam.
    Walsh N; Gibbie TM; Higgs P
    Drug Alcohol Rev; 2008 Mar; 27(2):200-3. PubMed ID: 18264883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.